{"pmid":32185369,"title":"Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor.","text":["Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor.","Arch Acad Emerg Med","Rismanbaf, Ali","Zarei, Sara","32185369"],"journal":"Arch Acad Emerg Med","authors":["Rismanbaf, Ali","Zarei, Sara"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32185369","week":"202012|Mar 16 - Mar 22","keywords":["Acute kidney injury","Coronavirus","Drug therapy","Liver Failure"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661633092445536256,"score":6.786717,"similar":[{"pmid":32145717,"title":"[Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored].","text":["[Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored].","Zhonghua Yi Xue Za Zhi","Yang, X H","Sun, R H","Chen, D C","32145717"],"journal":"Zhonghua Yi Xue Za Zhi","authors":["Yang, X H","Sun, R H","Chen, D C"],"date":"2020-03-09T11:00:00Z","year":2020,"_id":"32145717","week":"202011|Mar 09 - Mar 15","doi":"10.3760/cma.j.cn112137-20200229-00520","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1661359647786795008,"score":60.987907},{"pmid":32075364,"title":"[Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy].","text":["[Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy].","The outbreak of novel coronavirus pneumonia(NCP) caused by 2019 novel coronavirus has become a global public health challenge. Some patients accompany with liver function damage in addition to the main typical respiratory symptom. Here we analyzed the clinical features, susceptible population, potential causes and therapeutic strategies of NCP related liver injury.","Zhonghua Gan Zang Bing Za Zhi","Hu, L L","Wang, W J","Zhu, Q J","Yang, L","32075364"],"abstract":["The outbreak of novel coronavirus pneumonia(NCP) caused by 2019 novel coronavirus has become a global public health challenge. Some patients accompany with liver function damage in addition to the main typical respiratory symptom. Here we analyzed the clinical features, susceptible population, potential causes and therapeutic strategies of NCP related liver injury."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Hu, L L","Wang, W J","Zhu, Q J","Yang, L"],"date":"2020-02-21T11:00:00Z","year":2020,"_id":"32075364","week":"20208|Feb 17 - Feb 23","doi":"10.3760/cma.j.issn.1007-3418.2020.02.001","keywords":["Angiotensin converting enzyme2","Liver injury","Novel coronavirus pneumonia","Sever acute respiratory syndrome coronavirus 2"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647334858752,"score":47.498577},{"pmid":32145190,"title":"Liver injury in COVID-19: management and challenges.","text":["Liver injury in COVID-19: management and challenges.","Lancet Gastroenterol Hepatol","Zhang, Chao","Shi, Lei","Wang, Fu-Sheng","32145190"],"journal":"Lancet Gastroenterol Hepatol","authors":["Zhang, Chao","Shi, Lei","Wang, Fu-Sheng"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32145190","week":"202010|Mar 02 - Mar 08","doi":"10.1016/S2468-1253(20)30057-1","source":"PubMed","weight":0,"_version_":1661359647789940736,"score":42.98399},{"pmid":31996494,"title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV).","text":["Drug treatment options for the 2019-new coronavirus (2019-nCoV).","As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), arbidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.","Biosci Trends","Lu, Hongzhou","31996494"],"abstract":["As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), arbidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments."],"journal":"Biosci Trends","authors":["Lu, Hongzhou"],"date":"2020-01-31T11:00:00Z","year":2020,"_id":"31996494","week":"20205|Jan 27 - Feb 02","doi":"10.5582/bst.2020.01020","keywords":["*2019-nCoV","*Coronaviruses","*pneumonia"],"source":"PubMed","locations":["Chinese","Capsules","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647039160320,"score":40.53645},{"pmid":32179150,"title":"Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?","text":["Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?","In December 2019, a new coronavirus, named SARS-CoV-2, has emerged from China causing pneumonia outbreaks first in the Wuhan region and have now spread worldwide because of its probable high transmission efficiency. Due to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococci infection, previously showed efficacy to inhibit the first stage of MERS-coronarivus viral cycle in human cells. This activity is conserved on the SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.","Int J Antimicrob Agents","Baron, Sophie Alexandra","Devaux, Christian","Colson, Philippe","Raoult, Didier","Rolain, Jean-Marc","32179150"],"abstract":["In December 2019, a new coronavirus, named SARS-CoV-2, has emerged from China causing pneumonia outbreaks first in the Wuhan region and have now spread worldwide because of its probable high transmission efficiency. Due to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococci infection, previously showed efficacy to inhibit the first stage of MERS-coronarivus viral cycle in human cells. This activity is conserved on the SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus."],"journal":"Int J Antimicrob Agents","authors":["Baron, Sophie Alexandra","Devaux, Christian","Colson, Philippe","Raoult, Didier","Rolain, Jean-Marc"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32179150","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.ijantimicag.2020.105944","keywords":["COVID-19","Drug repurposing","SARS-CoV-2","Teicoplanin"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661542091955634176,"score":40.53645}]}